TG Therapeutics
Presença
TG Therapeutics é uma das ...
TG Therapeutics é uma empresa listada sob o símbolo TGTX (US).
Executivos
Veja o organograma con seus 10 executivos principais
Biografias mais buscadas da TG Therapeutics
- Michael Weiss, Executive Chairman, President and Chief Executive O...
- Laurence Charney, Director
- Kenneth Hoberman, Director
Criar um alerta
para seguir os movimentos de executivos da TG Therapeutics.
Farmacêutica
TG Therapeutics possui 1.860 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacêutica
- MedMen has filed for bankruptcy protection (publicado em 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de TG Therapeutics
- TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology | TG Therapeutics, Inc.
- TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting | TG Therapeutics, Inc.
- TG Therapeutics Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMS | TG Therapeutics, Inc.
- TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting | TG Therapeutics, Inc.
- TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference | TG Therapeutics, Inc.
- TG Therapeutics to Participate in the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference | TG Therapeutics, Inc.
- TG Therapeutics Announces Fast Track Designation Granted by the FDA to Ublituximab in Combination with Umbralisib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia | TG Therapeutics, Inc.
- RSS News Feeds | TG Therapeutics, Inc.
- TG Therapeutics to Present at Upcoming Investor Conferences | TG Therapeutics, Inc.
- TG Therapeutics Announces FDA Acceptance of New Drug Application for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma and Follicular Lymphoma | TG Therapeutics, Inc.
- View more press releases Close
Redes sociais sobre TG Therapeutics
- TG Therapeutics na Wikipedia, Google News e Yahoo Finance
- TG Therapeutics na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Michael Weiss 
Ligue para a TG Therapeutics em +1 212...
